Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid in men with osteoporosis
2006-005893-37Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Zoledronic acid + calcium + vitamin D with Placebo + calcium + vitamin D (2 arms). Primary endpoint: Percent change in bone mineral density at lumbar spine and/or total hip at Month 12. Started Apr 2007; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2006-005893-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005893-37.